Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and protection from stroke

References

• Carandang R, Seshadri S, Beiser A et al. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA296, 2939–2946 (2006).
   PubMed Web of Science ®Google Scholar
• MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335, 765–774 (1990).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet335, 827–838 (1990).
   PubMed Web of Science ®Google Scholar
• Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J. Am. Coll. Cardiol.27, 1214–1218 (1996).
   PubMed Web of Science ®Google Scholar
• Moser M. Update on the management of hypertension: recent clinical trials and the JNC 7. J. Clin. Hypertens. (Greenwich)6(Suppl. 2), 4–13 (2004).
   PubMedGoogle Scholar
• Verdecchia P, Reboldi G, Angeli F et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension46, 386–392 (2005).
   PubMed Web of Science ®Google Scholar
• Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic protein-1. Clin. Sci. (Lond).103, 131–136 (2002).
   PubMed Web of Science ®Google Scholar
• Gasic S, Wagner OF, Fasching P et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive Type II diabetic patients with microalbuminuria. Am. J. Hypertens.12, 217–222 (1999).
   PubMed Web of Science ®Google Scholar
• Hlubocka Z, Umnerova V, Heller S et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor – markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors. J. Hum. Hypertens.16, 557–562 (2002).
   PubMed Web of Science ®Google Scholar
• Li J, Culman J, Hortnagl H et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J.19, 617–619 (2005).
   PubMed Web of Science ®Google Scholar
• Iwai M, Liu HW, Chen R et al. Possible inhibition of focal cerebral ischemia by angiotensin II Type 2 receptor stimulation. Circulation110, 843–848 (2004).
   PubMed Web of Science ®Google Scholar
• Krikov M, Thone-Reineke C, Muller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J. Hypertens.26, 544–552 (2008).
   PubMed Web of Science ®Google Scholar
• Dai W, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke30, 2391–2399 (1999).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al.; MOSES Study Group. Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Dahlöf B, Shimizu M et al.; Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet369, 1431–1439 (2007).
   PubMed Web of Science ®Google Scholar
• The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med.358, 1547–1559 (2008).
   PubMed Web of Science ®Google Scholar
• Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J. Hypertens.26, 1282–1289 (2008).
   PubMed Web of Science ®Google Scholar
• Verma S, Strauss M. Angiotensin receptor blocker and myocardial infarction. BMJ329, 1248–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Vickrey BG, Rector TS, Wickstrom SL et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke33, 901–906 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou M, Offer A, Yang G et al. Body mass index, blood pressure, and mortality from stroke: a nationally representative prospective study of 212,000 Chinese men. Stroke39, 753–759 (2008).
   PubMed Web of Science ®Google Scholar